JPH11502710A5 - - Google Patents

Info

Publication number
JPH11502710A5
JPH11502710A5 JP1996529348A JP52934896A JPH11502710A5 JP H11502710 A5 JPH11502710 A5 JP H11502710A5 JP 1996529348 A JP1996529348 A JP 1996529348A JP 52934896 A JP52934896 A JP 52934896A JP H11502710 A5 JPH11502710 A5 JP H11502710A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1996529348A
Other languages
English (en)
Japanese (ja)
Other versions
JP4510147B2 (ja
JPH11502710A (ja
Filing date
Publication date
Priority claimed from US08/414,417 external-priority patent/US5801005A/en
Application filed filed Critical
Publication of JPH11502710A publication Critical patent/JPH11502710A/ja
Publication of JPH11502710A5 publication Critical patent/JPH11502710A5/ja
Application granted granted Critical
Publication of JP4510147B2 publication Critical patent/JP4510147B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP52934896A 1995-03-31 1996-03-28 悪性腫瘍の予防または処置のためのher−2/neuタンパク質の細胞内ドメイン Expired - Fee Related JP4510147B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/414,417 US5801005A (en) 1993-03-17 1995-03-31 Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US08/414,417 1995-03-31
PCT/US1996/001689 WO1996030514A1 (en) 1995-03-31 1996-03-28 Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007237635A Division JP2008056679A (ja) 1995-03-31 2007-09-13 悪性腫瘍の予防または処置のためのher−2/neuタンパク質の細胞内ドメイン

Publications (3)

Publication Number Publication Date
JPH11502710A JPH11502710A (ja) 1999-03-09
JPH11502710A5 true JPH11502710A5 (enExample) 2005-04-07
JP4510147B2 JP4510147B2 (ja) 2010-07-21

Family

ID=23641368

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52934896A Expired - Fee Related JP4510147B2 (ja) 1995-03-31 1996-03-28 悪性腫瘍の予防または処置のためのher−2/neuタンパク質の細胞内ドメイン
JP2007237635A Pending JP2008056679A (ja) 1995-03-31 2007-09-13 悪性腫瘍の予防または処置のためのher−2/neuタンパク質の細胞内ドメイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007237635A Pending JP2008056679A (ja) 1995-03-31 2007-09-13 悪性腫瘍の予防または処置のためのher−2/neuタンパク質の細胞内ドメイン

Country Status (19)

Country Link
US (9) US5801005A (enExample)
EP (2) EP1418235A3 (enExample)
JP (2) JP4510147B2 (enExample)
KR (1) KR100554186B1 (enExample)
CN (3) CN1951398A (enExample)
AT (1) ATE299180T1 (enExample)
AU (1) AU708237B2 (enExample)
BR (1) BR9607889A (enExample)
CA (1) CA2216601C (enExample)
CZ (2) CZ296618B6 (enExample)
DE (1) DE69634912T2 (enExample)
DK (1) DK0817846T3 (enExample)
ES (1) ES2245783T3 (enExample)
HU (1) HUP9801826A3 (enExample)
NO (2) NO321941B1 (enExample)
NZ (1) NZ306616A (enExample)
PT (1) PT817846E (enExample)
RU (2) RU2236461C2 (enExample)
WO (1) WO1996030514A1 (enExample)

Families Citing this family (352)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
FI972514A7 (fi) * 1994-12-14 1997-08-12 Scripps Research Inst Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
DK0910407T3 (da) * 1996-05-15 2003-06-16 Altarex Inc Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
DE69839553D1 (de) * 1997-01-08 2008-07-10 Invitrogen Corp Verfahren zur herstellung von proteinen
ATE235890T1 (de) * 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999057981A1 (en) * 1998-05-08 1999-11-18 Sloan-Kettering Institute For Cancer Research Compositions and methods for active vaccination
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
KR101063278B1 (ko) * 1998-08-11 2011-09-07 바이오겐 아이덱 인크. B-세포 림프종을 치료하기 위한 항-cd20 항체를 포함하는 약제
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
AU761516B2 (en) * 1998-11-09 2003-06-05 Biogen Inc. Chimeric anti-CD20 antibody treatment of patients receiving BMT or PBSC transplants
EP1131093A4 (en) 1998-11-09 2002-05-02 Idec Pharma Corp TREATMENT OF HEMATOLOGICAL VILTIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODIES
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
WO2000044225A1 (en) 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu
IL144371A0 (en) * 1999-01-29 2002-05-23 Corixa Corp Her-2/neu fusion proteins
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
EP1165144A2 (en) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
EP1187849A1 (en) * 1999-05-25 2002-03-20 Human Genome Sciences, Inc. Meth1 and meth2 polynucleotides and polypeptides
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
PT1189634E (pt) * 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP1246597B1 (en) * 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
NZ517150A (en) 1999-08-27 2005-01-28 Genentech Inc Dosages for treatment with anti-ErbB2 antibodies
WO2001021192A2 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
US20030157119A1 (en) * 1999-09-22 2003-08-21 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AU7743100A (en) * 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2801106B1 (fr) * 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
AU2744201A (en) * 1999-12-29 2001-07-09 Corixa Corporation Murine neu sequences and methods of use therefor
US20020039573A1 (en) * 2000-01-21 2002-04-04 Cheever Martin A. Compounds and methods for prevention and treatment of HER-2/neu associated malignancies
US6528060B1 (en) * 2000-03-16 2003-03-04 Genzyme Corporation Therapeutic compounds
DK1272633T3 (da) * 2000-03-30 2011-05-23 Dendreon Corp Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi
IL152054A0 (en) * 2000-04-13 2003-05-29 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
EP1282443B1 (en) * 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
US7229623B1 (en) * 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
HUP0600780A2 (en) * 2000-08-14 2007-01-29 Corixa Corp Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
AU2001283360A1 (en) * 2000-08-14 2002-02-25 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
KR100831139B1 (ko) 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP1404359A2 (en) * 2000-12-07 2004-04-07 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
CA2698079C (en) 2001-02-20 2015-01-13 Ortho-Mcneil Pharmaceutical, Inc. A cell therapy method for the treatment of tumors
EP1236740B1 (de) * 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
EP2371854B1 (en) * 2001-03-09 2014-05-07 Board Of Regents, The University Of Texas System Induction of tumor immunity by variants of folate binding protein
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
JP4608210B2 (ja) 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド キメラアルファウイルスレプリコン粒子
ATE345812T1 (de) * 2001-09-03 2006-12-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Antigen-mimotope und vakzine gegen krebserkrankungen
US7718387B2 (en) 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
EP1482963A4 (en) 2002-03-08 2010-06-09 Univ Texas CONTROLLED MODULATION OF THE AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGEN
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
KR20130012595A (ko) 2002-08-12 2013-02-04 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
US20080019992A1 (en) * 2002-09-02 2008-01-24 Christoph Zielinski Antigen mimotopes and vaccine against cancerous diseases
CN1497255A (zh) * 2002-10-02 2004-05-19 ���µ�����ҵ��ʽ���� 被检测体用取样元件、被检测体处理装置及其处理方法
EP1560651A1 (en) * 2002-11-12 2005-08-10 Millipore Corporation Evaporation control device for multiwell plates
GB2424070B (en) * 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
EP1572972A4 (en) * 2002-11-21 2007-11-21 Genentech Inc THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
US7282365B2 (en) 2003-01-03 2007-10-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Rhesus HER2/neu, nucleotides encoding same, and uses thereof
WO2004067716A2 (en) * 2003-01-24 2004-08-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
CN1759122B (zh) * 2003-03-03 2012-06-13 得克萨斯州大学系统董事会 包含mda-7的组合物和方法
AU2004232971A1 (en) * 2003-04-18 2004-11-04 Idm Pharma Inc. HLA-A2 tumor associated antigen peptides and compositions
JP2007525187A (ja) * 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
JP5283335B2 (ja) * 2003-06-17 2013-09-04 マンカインド コーポレイション 各種癌の治療を目的とした腫瘍関連抗原の組合せ
RU2397249C2 (ru) * 2003-07-21 2010-08-20 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа СИНТЕТИЧЕСКАЯ МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ КЛЕТОК МЛЕКОПИТАЮЩЕГО, КЛЕТКА МЛЕКОПИТАЮЩЕГО ХОЗЯИНА И СПОСОБ ЭКСПРЕССИИ ЧЕЛОВЕЧЕСКОГО БЕЛКА АНТИГЕНА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА-2 (HER2/neu) ИЛИ ЕГО УКОРОЧЕННОЙ ФОРМЫ
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
EP1684580A2 (en) 2003-10-22 2006-08-02 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in tissues and organs
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
CA2548220A1 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CA2565974A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
AU2005250432B2 (en) 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 免疫増強用の化合物
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
CA2583230A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
MX2007004079A (es) * 2004-10-06 2007-06-15 Wellstat Biologics Corp Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
KR101294290B1 (ko) * 2004-12-29 2013-08-07 맨카인드 코포레이션 예방 또는 치료를 위해 제i류 주조직 적합성복합체〔mhc〕-제한 에피토프에 대한 면역 반응을 유발,향상 및 지속하는 방법
WO2006086798A2 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
AU2006236150A1 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
CN100398558C (zh) * 2005-05-10 2008-07-02 中国人民解放军军事医学科学院基础医学研究所 HER2/neu与Herstatin相互作用的活性片段及其编码基因与应用
JP2008544962A (ja) * 2005-05-12 2008-12-11 イントロゲン セラピューティックス, インコーポレイテッド 癌の治療のためのp53ワクチン
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
SI1889059T1 (sl) 2005-05-27 2009-12-31 Oncimmune Ltd Izboljšani imunotestni postopek
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
ES2531483T3 (es) * 2005-06-15 2015-03-16 The Ohio State University Research Foundation Péptidos HER-2
JP5416968B2 (ja) 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1933857A2 (en) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
EP1933864A4 (en) * 2005-09-07 2009-12-16 Receptor Logic Ltd ANTIBODIES AS T-CELL RECEPTOR MIMICS, METHOD OF MANUFACTURE AND ITS USES
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
WO2007030771A2 (en) * 2005-09-08 2007-03-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP1945247A1 (en) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) * 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
US7517270B2 (en) * 2006-05-30 2009-04-14 Minds-I, Inc. Construction system
JP2009544974A (ja) 2006-07-21 2009-12-17 ライフ テクノロジーズ コーポレーション 鮮明に分解する標識タンパク質分子量標準
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
CN101632020B (zh) * 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
EP2064229B1 (en) 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Oncolytic rhabdovirus
WO2008036776A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20080075528A1 (en) * 2006-09-22 2008-03-27 Michael Marzetta Construction system
US8129184B2 (en) * 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) * 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
AU2007333106A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. miR-20 regulated genes and pathways as targets for therapeutic intervention
US7935350B2 (en) * 2006-12-14 2011-05-03 Antigen Express, Inc. Ii-key/Her-2/neu hybrid cancer vaccine
US8889143B2 (en) 2006-12-14 2014-11-18 Antigen Express, Inc. Ii-key/HER-2/neu hybrid cancer vaccine
US7410225B1 (en) * 2007-03-14 2008-08-12 Minds-I, Inc. Multi-part links for endless track
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
CA2684265A1 (en) * 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
WO2008150577A1 (en) 2007-06-01 2008-12-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US20090017716A1 (en) * 2007-07-11 2009-01-15 Michael Marzetta Construction system
US20090061456A1 (en) * 2007-08-30 2009-03-05 Allard William J Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090117532A1 (en) * 2007-11-01 2009-05-07 Doyle Gerald V Pre-clinical method for monitoring serial changes in circulating breast cancer cells in mice
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
US7841923B2 (en) * 2007-11-13 2010-11-30 Minds-I, Inc. Vehicle axle joint for a toy vehicle
CN101878429B (zh) * 2007-11-27 2015-05-20 维里德克斯有限责任公司 血液中循环黑素瘤细胞的自动化计数和表征
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20090191535A1 (en) * 2007-12-22 2009-07-30 Mark Carle Connelly Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Her2サブセット
WO2010028066A2 (en) 2008-09-02 2010-03-11 Cedars-Sinai Medical Center Cd133 epitopes
BRPI0922849B1 (pt) 2008-12-10 2023-01-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Composição de vacina com uma quantidade eficaz de um peptídeo gp2 e de gm-csf
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
US20110065643A1 (en) * 2009-06-12 2011-03-17 University Of Southern California Clusterin Pharmaceuticals and Treatment Methods Using the Same
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
EP2477499B1 (en) 2009-09-14 2018-04-11 SillaJen Biotherapeutics, Inc. Oncolytic vaccinia virus combination cancer therapy
MX365946B (es) 2009-12-10 2019-06-19 Turnstone Lp Rabdovirus oncolitico.
WO2011107100A1 (en) 2010-03-03 2011-09-09 Aarhus Universitet Methods and compositions for regulation of herv4
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
JP2014506791A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド miR−34の合成模倣体
CN105969773A (zh) 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
WO2012167382A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
US8663637B2 (en) 2011-08-05 2014-03-04 Research Development Foundation Methods and compositions for modulation of Olfml3 mediated angiogenesis
US10258676B2 (en) 2011-09-06 2019-04-16 Agency For Science, Technology And Research Polypeptide vaccine
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9814767B2 (en) 2012-02-17 2017-11-14 Mayo Foundation For Medical Education And Research Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US20150283233A1 (en) 2012-06-15 2015-10-08 Gencia Corporation Compositions and Methods for Enhancing Immune Responses
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
WO2014057122A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
PT2906298T (pt) 2012-10-12 2018-12-28 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpos
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SMT201800346T1 (it) 2012-10-12 2018-09-13 Medimmune Ltd Coniugati pirrolobenzodiazepina-anticorpo
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
CA2888345C (en) 2012-10-24 2020-04-21 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
JP6307519B2 (ja) 2012-12-21 2018-04-04 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびその結合体
EP2956544B1 (en) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Cancer vaccines and vaccination methods
CN105658790A (zh) 2013-02-21 2016-06-08 东安大略研究所儿童医院有限公司 疫苗组合物
EP2968596B1 (en) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン及びそのコンジュゲート
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015023879A1 (en) 2013-08-14 2015-02-19 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
AU2014308699C1 (en) 2013-08-21 2022-06-02 Board Of Regents, The University Of Texas System Compositions and methods for targeting connexin hemichannels
US10363311B2 (en) 2013-08-29 2019-07-30 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
US9808486B2 (en) 2013-08-30 2017-11-07 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP2017501694A (ja) 2013-12-04 2017-01-19 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 診断および療法のためのエキソソーム中のゲノムdna、rnaおよびタンパク質の分析
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック, インコーポレイテッド 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
US10457676B2 (en) 2014-08-29 2019-10-29 The Board Of Regents Of The University Of Texas System Capsazepine analogs for the treatment of cancer and other proliferative diseases
IL250833B (en) 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック, インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック, インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
RU2721953C2 (ru) 2015-03-04 2020-05-25 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Способы лечения рака, имеющего гемизиготную потерю тр53
JP2018515742A (ja) * 2015-03-13 2018-06-14 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 癌のcd4+tヘルパー1型応答の監視方法および免疫回復
US20180171294A1 (en) * 2015-03-26 2018-06-21 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EP3302539A4 (en) * 2015-05-22 2018-12-19 Brian J. Czerniecki Manufacturing multi-dose injection ready dendritic cell vaccines
WO2016196506A1 (en) 2015-05-29 2016-12-08 Galena Biopharma, Inc. PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRα-EXPRESSING TUMORS
EA201890006A1 (ru) 2015-06-10 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Применение экзосом для лечения болезни
RU2612015C2 (ru) * 2015-06-29 2017-03-01 Общество с ограниченной ответственностью "Сибинтех" Пептид-иммуноген, используемый в терапевтической вакцине для лечения метастатического рака молочной железы у кошек и собак
US9956172B2 (en) 2015-07-28 2018-05-01 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
EA038277B1 (ru) 2015-10-14 2021-08-04 Байо-Пат Холдингз, Инк. P-этокси нуклеиновые кислоты для липосомальной лекарственной формы
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
RU2624862C2 (ru) * 2015-10-20 2017-07-07 Общество с ограниченной ответственностью "Эпитек" Пептид-иммуноген, используемый в терапевтической вакцине для лечения метастатического рака молочной железы
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
SI3373968T1 (sl) 2015-11-09 2024-10-30 The Children's Hospital Of Philadelphia Glipikan 2 kot marker raka in terapevtska tarča
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
ES2861449T3 (es) 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CA3015839A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
CA3016457A1 (en) 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
JP7241541B2 (ja) 2016-03-29 2023-03-17 エスティーキューブ,インコーポレイテッド グリコシル化pd-l1に特異的な二重機能抗体およびその使用方法
JP7572146B2 (ja) 2016-03-29 2024-10-23 エスティーキューブ アンド カンパニー,インコーポレイテッド グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
DK3449017T3 (da) 2016-04-29 2022-03-14 Univ Texas Målrettet måling af transkriptionel aktivitet vedrørende hormonreceptorer
DK3458074T3 (da) 2016-05-16 2024-07-29 Univ Texas COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
WO2017210255A1 (en) 2016-05-31 2017-12-07 Galena Biopharma, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
JP2019521099A (ja) * 2016-06-03 2019-07-25 エトゥビクス コーポレーション Her2/neuを含む、腫瘍ワクチン接種及び免疫療法のための組成物及び方法
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
KR20190026813A (ko) 2016-07-06 2019-03-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 시스틴의 인간-효소 매개된 고갈
EP3487883B1 (en) 2016-07-20 2023-01-04 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
US9963498B2 (en) 2016-08-18 2018-05-08 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
MX2019003070A (es) 2016-09-16 2019-10-14 Bio Path Holdings Inc Terapia de combinacion con oligonucleotidos antisentido liposomales.
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018089423A1 (en) 2016-11-09 2018-05-17 Musc Foundation For Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
KR102771603B1 (ko) 2016-11-17 2025-02-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
CN110612447B (zh) 2017-02-24 2024-02-06 德克萨斯州立大学董事会 用于检测早期胰腺癌的测定
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CN110603324A (zh) 2017-05-12 2019-12-20 得克萨斯大学体系董事会 用于治疗高同型半胱氨酸血症和同型胱胺酸尿症患者的人类酶介导的同型半胱氨酸耗竭
US10865403B2 (en) 2017-05-12 2020-12-15 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
AU2018277545B2 (en) 2017-05-31 2025-05-15 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
US11542331B2 (en) 2017-06-06 2023-01-03 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
ES2988683T3 (es) 2017-06-14 2024-11-21 Adc Therapeutics Sa Pautas posológicas para la administración de un CAF anti-CD19
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20220156974A (ko) 2017-09-20 2022-11-28 주식회사 피에이치파마 타일란스타틴 유사체
WO2019075097A1 (en) 2017-10-11 2019-04-18 Board Of Regents, The University Of Texas System PD-L1 HUMAN ANTIBODIES AND METHODS OF USE
WO2019075385A1 (en) 2017-10-12 2019-04-18 Board Of Regents, The University Of Texas System T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
CA3079999A1 (en) 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2020036635A2 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2019182867A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
BR112020019251A2 (pt) 2018-03-27 2021-01-12 Board Of Regents, The University Of Texas System Compostos com atividade anti-tumor contra células de câncer com mutações de her2 exon 19
CN112513297B (zh) 2018-03-28 2024-10-22 得克萨斯州大学系统董事会 鉴定从外排体分离的dna中的表观遗传改变
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN108624589B (zh) * 2018-04-17 2021-12-17 广州永诺生物科技有限公司 环状RNA circ-ERBB2及其检测试剂与应用
JP7529265B2 (ja) 2018-04-19 2024-08-06 ベイラー カレッジ オブ メディスン CD8abおよびクラス1制限T細胞受容体の強制発現による細胞傷害性CD8細胞へのCD4 T細胞の再プログラミング
US12115262B2 (en) 2018-05-24 2024-10-15 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
CN108484732A (zh) * 2018-06-08 2018-09-04 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108715603A (zh) * 2018-06-08 2018-10-30 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
EP3883955A1 (en) 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
CA3121027A1 (en) 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
WO2020123388A1 (en) 2018-12-11 2020-06-18 Board Of Regents, The University Of Texas System Radiotherapies and uses thereof
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CA3129248A1 (en) 2019-02-08 2020-08-13 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
CN114144514B (zh) 2019-05-09 2025-11-25 富士胶片细胞动力公司 产生肝细胞的方法
US10945981B2 (en) 2019-05-17 2021-03-16 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
CN119925596A (zh) 2019-07-19 2025-05-06 费城儿童医院 包含磷脂酰肌醇蛋白聚糖2结合结构域的嵌合抗原受体
EP4027978A1 (en) 2019-09-13 2022-07-20 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
WO2021062323A1 (en) 2019-09-26 2021-04-01 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
JP2022552282A (ja) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー グリコシル化lag3に対して特異的な抗体およびその使用方法
WO2021087458A2 (en) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
KR20220124718A (ko) 2020-01-07 2022-09-14 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 개선된 인간 메틸 티오아데노신/아데노신 고갈 효소 변이체
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021212019A1 (en) 2020-04-17 2021-10-21 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
CA3178726A1 (en) 2020-05-21 2021-11-25 Gregory LIZEE T cell receptors with vgll1 specificity and uses thereof
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
WO2022006286A1 (en) 2020-06-30 2022-01-06 Lunglife Ai Methods for detecting lung cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2022159492A1 (en) 2021-01-19 2022-07-28 William Marsh Rice University Bone-specific delivery of polypeptides
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
CA3228262A1 (en) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
CN115925875A (zh) * 2021-08-20 2023-04-07 百奥赛图(北京)医药科技股份有限公司 Her2基因人源化非人动物及其构建方法和应用
WO2023060136A1 (en) 2021-10-05 2023-04-13 Cytovia Therapeutics, Llc Natural killer cells and methods of use thereof
CN113699221B (zh) * 2021-10-19 2023-10-10 广州吉赛医疗科技有限公司 HER2 mRNA及环状RNA多重荧光定量PCR检测引物探针及其应用
MX2024004365A (es) 2021-10-20 2024-04-25 Takeda Pharmaceuticals Co Composiciones que actuan sobre el antigeno de maduracion de linfocitos b (bcma) y metodos de uso de las mismas.
US20240409934A1 (en) 2021-10-25 2024-12-12 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN114262689A (zh) * 2021-12-17 2022-04-01 上海纳米技术及应用国家工程研究中心有限公司 一种快速检测cd19/cd20-car-t细胞活性的方法
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
IL316011A (en) 2022-04-01 2024-11-01 Univ Texas Dual specific antibodies to human PD-L1 and PD-L2 and methods of using them
EP4514382A1 (en) 2022-04-28 2025-03-05 Musc Foundation for Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
CA3257006A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
WO2023230531A1 (en) 2022-05-24 2023-11-30 Lunglife Ai, Inc. Methods for detecting circulating genetically abnormal cells
IL317568A (en) 2022-06-10 2025-02-01 Res Found Dev Engineered FCRIIB Selective IgG1 FC Variants, and Their Uses
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
CN116042657A (zh) * 2023-01-16 2023-05-02 上海复诺健生物科技有限公司 自复制信使核糖核酸疫苗
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3766162A (en) * 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) * 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4452901A (en) * 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
WO1990014357A1 (en) * 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
DK0444181T3 (da) * 1989-08-04 2002-02-25 Schering Ag C-erbB-2 eksternt domæne: gp75
DE69108716T2 (de) * 1990-01-26 1995-08-17 Washington Research Foundation, Seattle, Wash. Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.
US5958784A (en) * 1992-03-25 1999-09-28 Benner; Steven Albert Predicting folded structures of proteins
CA2157510A1 (en) * 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
FI972514A7 (fi) * 1994-12-14 1997-08-12 Scripps Research Inst Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie

Similar Documents

Publication Publication Date Title
JPH11502710A5 (enExample)
JP2000500033A5 (enExample)
JPH11511357A5 (enExample)
JP2000500445A5 (enExample)
JP2000500440A5 (enExample)
JP2000500327A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500406A5 (enExample)
JP2000501377A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JPH10503912A5 (enExample)
JP2000500322A5 (enExample)
JP2000500342A5 (enExample)
JPH11500872A5 (enExample)
JP2000500112A5 (enExample)
JP2000500051A5 (enExample)
JP2000500397A5 (enExample)
JP2000500407A5 (enExample)
JP2000500019A5 (enExample)
JP2000500166A5 (enExample)
JP2000500125A5 (enExample)
JP2000500044A5 (enExample)
JP2000500346A5 (enExample)